Kevin A Hommel1, Elizabeth Hente, Michele Herzer, Lisa M Ingerski, Lee A Denson. 1. Division of Behavioral Medicine and Clinical Psychology, Center for the Promotion of Treatment Adherence and Self-Management, Cincinnati Children's Hospital Medical Center, MLC 7039, Cincinnati, OH 45229-3039, USA. kevin.hommel@cchmc.org
Abstract
OBJECTIVE: To evaluate an individually tailored multicomponent nonadherence treatment protocol using a telehealth delivery approach in adolescents with inflammatory bowel disease. METHODS: Nine participants, age 13.71±1.35 years, completed a brief treatment online through Skype. Medication nonadherence, severity of disease, and feasibility/acceptability data were obtained. RESULTS: Adherence increased markedly from 62% at baseline to 91% for mesalamine (δ=0.63), but decreased slightly from 61% at baseline to 53% for 6-mercaptopurine /azathioprine. The telehealth delivery approach resulted in cost savings of $100 in mileage and 4 h of travel time/patient. Treatment session attendance was 100%, and the intervention was rated as acceptable, particularly in terms of treatment convenience. CONCLUSION: Individually tailored treatment of nonadherence through telehealth delivery is feasible and acceptable. This treatment shows promise for clinical efficacy to improve medication adherence and reduce costs. Large-scale testing is necessary to determine the impact of this intervention on adherence and health outcomes.
OBJECTIVE: To evaluate an individually tailored multicomponent nonadherence treatment protocol using a telehealth delivery approach in adolescents with inflammatory bowel disease. METHODS: Nine participants, age 13.71±1.35 years, completed a brief treatment online through Skype. Medication nonadherence, severity of disease, and feasibility/acceptability data were obtained. RESULTS: Adherence increased markedly from 62% at baseline to 91% for mesalamine (δ=0.63), but decreased slightly from 61% at baseline to 53% for 6-mercaptopurine /azathioprine. The telehealth delivery approach resulted in cost savings of $100 in mileage and 4 h of travel time/patient. Treatment session attendance was 100%, and the intervention was rated as acceptable, particularly in terms of treatment convenience. CONCLUSION: Individually tailored treatment of nonadherence through telehealth delivery is feasible and acceptable. This treatment shows promise for clinical efficacy to improve medication adherence and reduce costs. Large-scale testing is necessary to determine the impact of this intervention on adherence and health outcomes.
Authors: Kevin A Hommel; Michele Herzer; Lisa M Ingerski; Elizabeth Hente; Lee A Denson Journal: J Pediatr Gastroenterol Nutr Date: 2011-10 Impact factor: 2.839
Authors: Kevin A Hommel; Elizabeth A Hente; Shannon Odell; Michele Herzer; Lisa M Ingerski; Shanna M Guilfoyle; Lee A Denson Journal: Eur J Gastroenterol Hepatol Date: 2012-01 Impact factor: 2.566
Authors: Dan Turner; Anthony R Otley; David Mack; Jeffrey Hyams; J de Bruijne; Krista Uusoue; Thomas D Walters; Mary Zachos; Petar Mamula; Dorcas E Beaton; A Hillary Steinhart; Anne M Griffiths Journal: Gastroenterology Date: 2007-05-21 Impact factor: 22.682
Authors: Kevin A Hommel; Wendy N Gray; Elizabeth Hente; Katherine Loreaux; Richard F Ittenbach; Michele Maddux; Robert Baldassano; Francisco Sylvester; Wallace Crandall; Charles Doarn; Melvin B Heyman; David Keljo; Lee A Denson Journal: Contemp Clin Trials Date: 2015-05-21 Impact factor: 2.226
Authors: Sarah M Alexander; Alfred Agaba; Jeffrey I Campbell; Nuriat Nambogo; Carol S Camlin; Mallory Johnson; Grant Dorsey; Kristian R Olson; David R Bangsberg; Ryan W Carroll; Data Santorino; Paul J Krezanoski Journal: BMC Public Health Date: 2022-05-19 Impact factor: 4.135